AR037460A1 - Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion - Google Patents
Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacionInfo
- Publication number
- AR037460A1 AR037460A1 ARP020104587A ARP020104587A AR037460A1 AR 037460 A1 AR037460 A1 AR 037460A1 AR P020104587 A ARP020104587 A AR P020104587A AR P020104587 A ARP020104587 A AR P020104587A AR 037460 A1 AR037460 A1 AR 037460A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- groups
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuestos de hidroxietileno que tienen actividad inhibidora de Asp2 (b-secretasa, BACE1 o Memapsina). Procedimiento para su preparación, composiciones farmacéuticas que los contienen y a su uso en el tratamiento de enfermedades individualizadas por niveles elevados de b-amiloide o depósitos de b-amiloide, en particular, a la enfermedad de Alzheimer. Reivindicación 1: Un compuesto de hidroxietileno caracterizado porque responde a la fórmula (1), en la que: R1 representa un grupo de fórmula (2) ó (3); A1 representa CH2, O, S o NR5; A2 representa O, S o NR5; n1 representa un número entero de 1 a 3; R5 representa hidrógeno, alquilo C1-6 opcionalmente sustituido con uno o más grupos R11, cicloalquilo C3-8 opcionalmente sustituido con uno o más grupos R11, -(alquil C1-2)(cicloalquilo C3-8) o arilo; Ra representa halógeno; Rb representa -(alquilo C1-6) opcionalmente sustituido con uno o más grupos R11 o -(alquil C1-6)arilo; X1 representa N, -C(-R6)- o -C(-O-R7)-; X2 representa N, -C(R8)- o -C(-Y-R9)-; Y representa un enlace, CH2, O, S, CO, NR10, -N(R10)C(O)-, -C(O)N(R10)-, COO, arilo, heterociclilo o heteroarilo; R6 representa hidrógeno, halógeno, -(alquilo C1-6) opcionalmente sustituido con uno o más grupos R11, -(alquenilo C2-6), -(cicloalquilo C3-8), opcinalmente sustituido con uno o más grupos R11, -(alquil C1-2) (cicloalquilo C3-8), heteroarilo, heterociclilo o arilo; R8 representa halógeno o trifluorometilo; R7, R9 y R10 representan independientemente hidrógeno, -(alquilo C1-6) opcionalmente sustituido con uno o más grupos R11, -(alquenilo C2-6), -(cicloalquilo C3-8) opcionalmente sustituido con uno o más grupos R11, -(alquil C1-2) (cicloalquilo C3-8), heteroarilo, heterociclilo o arilo; W1 representa CO ó SO2; R2 representa -(alquilo C5-8), -(alquil C1-6)arilo, -(alquil C1-6)heteroarilo, -(alquil C1-6)heterociclilo, -(alquil C1-6)(cicloalquilo C3-8), -(alquil C1-6)-S-arilo, -(alquil C1-6)-O-arilo, -(alquil C1-6)-S-heteroarilo o -(alquil C1-6)-O-heteroarilo; R3 representa -(alquilo C1-6) opcionalmente sustituido con uno o más grupos R11 o propargilo; R4 representa -(alquilo C1-6) opcionalmente sustituido con uno o más grupos R11, -(alquil C1-6)arilo, -(alquil C1-6)heteroarilo, -(alquil C1-6)heterociclilo, -(alquil C1-6) (cicloalquilo C3-8), -(cicloalquilo C3-8) opcionalmente sustituido con uno o más grupos seleccionados de R11 y alquilo C1-6, o propargilo; w y x representan independientemente un número entero de 0 a 2; R11 representa halógeno, hidroxi, -COOH, -COOCH3, alcoxi C1-6, ciano o amino; o una de sus sales o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0128748A GB0128748D0 (en) | 2001-11-30 | 2001-11-30 | Novel compounds |
GB0214090A GB0214090D0 (en) | 2002-06-18 | 2002-06-18 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037460A1 true AR037460A1 (es) | 2004-11-10 |
Family
ID=26246821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104587A AR037460A1 (es) | 2001-11-30 | 2002-11-28 | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
Country Status (7)
Country | Link |
---|---|
US (1) | US6992103B2 (es) |
EP (1) | EP1448520A1 (es) |
JP (1) | JP2005514373A (es) |
AR (1) | AR037460A1 (es) |
AU (1) | AU2002365516A1 (es) |
TW (1) | TW200304374A (es) |
WO (1) | WO2003045913A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314302D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Novel compounds |
ATE402921T1 (de) | 2003-08-08 | 2008-08-15 | Schering Corp | Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren |
AU2004277981B2 (en) * | 2003-10-03 | 2009-10-01 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease |
US20070225374A1 (en) * | 2003-10-30 | 2007-09-27 | Elan Pharmaceuticals, Inc. | Hydroxypropyl Amides for the Treatment of Alzheimer's Disease |
PL1685142T3 (pl) * | 2003-11-11 | 2008-06-30 | Hoffmann La Roche | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera |
WO2005051914A1 (en) * | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
EP1697308B1 (en) * | 2003-12-19 | 2014-03-19 | Merck Sharp & Dohme Corp. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
AU2005236020A1 (en) * | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
ITTO20040343A1 (it) * | 2004-05-24 | 2004-08-24 | Rotta Res Lab Spa | Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo |
US7872009B2 (en) * | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7745484B2 (en) * | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
JP5274258B2 (ja) | 2005-11-21 | 2013-08-28 | アムジエン・インコーポレーテツド | β−セクレターゼ調節物質及び使用方法 |
US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
CA2654915C (en) * | 2006-06-29 | 2015-07-28 | F.Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
US20080277393A1 (en) * | 2007-05-07 | 2008-11-13 | True Charles W | Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods |
US8163909B2 (en) | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US8173810B2 (en) * | 2007-05-25 | 2012-05-08 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
CA2715835C (en) | 2008-02-29 | 2017-03-21 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
MX2011002705A (es) * | 2008-09-11 | 2011-09-09 | Amgen Inc | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso. |
US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
EP2504330A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2011090911A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
MX2012010657A (es) | 2010-03-15 | 2013-02-07 | Amgen Inc | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
EP2949648A1 (en) | 2014-05-30 | 2015-12-02 | IEO - Istituto Europeo di Oncologia Srl | Cyclopropylamine derivatives as histone demethylase inhibitors |
BR112016028219B1 (pt) | 2014-05-30 | 2022-12-06 | Istituto Europeo Di Oncologia S.R.L | Composto ou composição farmacêutica para uso no tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, processo para obtenção de um composto de fórmula (i) e uso do composto ou composição farmacêutica na fabricação de um medicamento para uso no tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CN106699594B (zh) * | 2016-12-29 | 2018-11-06 | 山东诚汇双达药业有限公司 | 一种碘普罗胺的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869024A (en) * | 1989-11-29 | 1999-02-09 | Bracco International B.V. | Methods and compositions for using non-ionic contrast agents to reduce the risk of clot formation in diagnostic procedures |
CA2029830A1 (en) * | 1989-11-29 | 1991-05-30 | Ramachandran S. Ranganathan | Nonionic radiographic contrast agents |
PL335484A1 (en) * | 1997-02-26 | 2000-04-25 | Pfizer | Derivatives of heteroarylhexamide, their production and application as selective inhibitors of mip-1a being assimilated by its ccr1 receptor |
US7119085B2 (en) * | 2000-03-23 | 2006-10-10 | Elan Pharmaceuticals, Inc. | Methods to treat alzheimer's disease |
NZ533107A (en) * | 2001-11-08 | 2007-04-27 | Upjohn Co | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
-
2002
- 2002-11-28 AR ARP020104587A patent/AR037460A1/es not_active Application Discontinuation
- 2002-11-28 TW TW091134543A patent/TW200304374A/zh unknown
- 2002-11-29 JP JP2003547365A patent/JP2005514373A/ja active Pending
- 2002-11-29 US US10/496,269 patent/US6992103B2/en not_active Expired - Fee Related
- 2002-11-29 WO PCT/EP2002/013515 patent/WO2003045913A1/en active Application Filing
- 2002-11-29 EP EP02790460A patent/EP1448520A1/en not_active Withdrawn
- 2002-11-29 AU AU2002365516A patent/AU2002365516A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1448520A1 (en) | 2004-08-25 |
WO2003045913A1 (en) | 2003-06-05 |
US20050085520A1 (en) | 2005-04-21 |
US6992103B2 (en) | 2006-01-31 |
TW200304374A (en) | 2003-10-01 |
JP2005514373A (ja) | 2005-05-19 |
AU2002365516A1 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037460A1 (es) | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion | |
ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
NO20031331L (no) | Substituerte amino-aza-cykloalkaner anvendelige mot malaria | |
NO20091892L (no) | Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre | |
CR9314A (es) | Derivado de espirocetal y uso del mismo como medicina para la diabetes | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
MY145075A (en) | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists. | |
IL151172A0 (en) | Amine derivatives, their preparation and use as bax modulators | |
AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
NO20023932D0 (no) | Nye forbindelser | |
DK1263722T3 (da) | Farmaceutiske sammensætninger, som indeholder azetidinderivat, nye azetidinderivater og fremstilling deraf | |
TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
NO20090327L (no) | Nye forbindelser 384 | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
NO20052683L (no) | Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
SE0403171D0 (sv) | New compounds | |
TW200740781A (en) | Novel compounds | |
UY27424A1 (es) | Agentes antidiabéticos | |
MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
NO20034215D0 (no) | Nye amider, fremstilling og terapeutisk anvendelse av modulatorer av CCR-reseptoraktivitet | |
HUP0300235A2 (hu) | Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
SE0401763D0 (sv) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |